Padua, Italy – A study by the University of Padua, CNR Padua, and the “Mario Negri” Institute in Milan has been published in Molecular Therapy Nucleic Acids under the title “Restoration of myogenesis in ALS-myocytes through miR-26a-5p-mediated Smad4 inhibition and its impact on motor neuron development”. The research paves the way for new...
Latest News
Turku, Finland – White blood cells, the cells of our immune system, fight against cancer, bacteria, and viruses. However, not all white blood cells destroy cancer cells and some can even promote cancer growth. The most important cell types that destroy cancer cells are cytotoxic T cells and natural killer...
Nashville, Tennessee – Inherited diseases of metabolism and immunity have more in common than previously recognized, according to a new study published in the journal Science Immunology. The findings point to a new set of metabolic genes that are important for the function of immune system T cells, and they...
New York, NY – An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine. The results could potentially lead to new therapies for patients with limited options and add to the significant...
Washington, D.C.—Legionnaires’ disease (LD), a rare and severe type of pneumonia, is a respiratory infection caused by species of Legionella bacteria. One of the most accurate ways to diagnose LD is to perform culture on samples from a patient’s lower respiratory tract, but those samples are difficult to obtain. In...
New York, NY – Researchers at NYU College of Dentistry and NYU Grossman School of Medicine are closer to understanding what drives the autoimmune disorder Sjögren’s disease, thanks to new discoveries about the role of calcium signaling, regulatory T cells, and interferon. Their latest study, published in Science Translational Medicine,...
Basel – Novartis today announced new data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The overall safety profile remains favorable following presymptomatic treatment, in the long-term follow-up period from clinical studies and in the real-world setting. These data were...
Basel – Novartis today announced data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential, one-time treatment and the only gene therapy for spinal muscular atrophy (SMA). New late-breaker data from the completed two-copy cohort of the Phase 3 SPR1NT clinical trial demonstrate age-appropriate milestone development in presymptomatic children...
Chapel Hill, North Carolina – UNC Health is now enrolling patients as part of a multicenter clinical trial for patients who have been newly diagnosed with glioblastoma (GBM). The phase 2b clinical study administers IGV-001, a combination immunotherapy developed by biotech company Imvax. UNC Health is one of multiple academic...
ZURICH, Switzerland – Fatigue is common in people with inflammatory rheumatic and musculoskeletal diseases (RMD). The causes of fatigue are not well understood, and it is likely that they vary between people and over time. From a patient perspective, fatigue has a significant and detrimental impact on daily life, and...